MonTa announces completion of phase I does-escalation
MonTa announces completion of our phase I dose-escalation study with completion of the last cohort [...]
MonTa Biosciences Granted Broad U.S. Patent for Lead Immunotherapy Drug MBS8
We are pleased to announce that MonTa Biosciences has been granted a key U.S. patent [...]
MBS8 preclinical data published in prestigious Journal of Immunology
MonTa shares publication of MBS8 and how our TLR7 agonist demonstrates superior anti tumor activity [...]
MonTa Biosciences Secures Key Patents in Israel, China, and Japan for MBS8
We are proud to announce that MonTa Biosciences has been granted patents in Israel, China, [...]
MonTa Biosciences announces completion of patient cohort in our phase I clinical trial
We are pleased to announce the successful completion of the current dose level study involving [...]
Come and meet us and discuss business and partnering at Bio International in San Diego June 3 to 6th
MonTa Biosciences CEO, Simon S Jensen will be attending Bio International in San Diego in [...]
Meet us in San Diego for SITC November 3-5, 2023
MonTa Biosciences will be joining the Society for Immunotherapy and Cancer Therapy (SITC) in San [...]
MonTa Biosciences treat the first patients with the highest dose of MBS8 ever
In the last week of September 2023 we dosed patient number 31 and 32 with [...]
Meet us at BIO International in Boston June 5-8 to discuss clinical development of MBS8
MonTas CEO; Simon S Jensen, PhD, will be joining the biggest partnership conference within Life [...]
New clinical site for MonTas phase I clinical trial in Madrid
We are happy to announce opening of a new clinical site for MonTas phase I [...]
MonTa Biosciences will be presenting very strong data on our immuno oncology technology at the annual meeting of AACR in Orlando
MonTa Biosciences will be presenting very strong data on our immuno oncology technology with our [...]
MonTa Biosciences open clinical sites in Madrid and Bruxelles
MonTa Bisciences have in January opened additionally 4 clinical sites in Madrid and Bruxelles. We [...]
MonTa Biosciences Announces Investment to Complete the Ongoing Phase I Monotherapy Trial on MBS8, and a Combination Phase IB/IIA Trial with MBS8 and a Currently Approved Oncology Drug.
COPENHAGEN, Denmark, October 20, 2022 — MonTa Biosciences, a clinical-stage biotechnology company focused on stimulating [...]
MonTa Biosciences featured in Nature pharmadealmakers magazine
MonTa Biosciences was featured as an upcoming biotech oncology company in Natures edition of pharmadealmakers. [...]
MonTa Biosciences successfully dose first patient in phase I clinical trial
MonTa Biosciences this week successfully enrolled and dosed the first cancer patient in our phase [...]
MonTa Biosciences awarded approval from regulatory agencies to start phase I study
MonTa Biosciences was awarded with positive feedback from the regulatory agency in Denmark to initiate [...]
MonTa Biosciences becomes a Clinical Stage Company
MonTa Biosciences today announced that the company has transitioned from a preclinical to a Clinical [...]
MonTa Biosciences initiates collaboration with NCI under the Nanotechnology Characterization Laboratory program
MonTa Biosciences has successfully gone through a tough selection process and been enrolled into the [...]
MonTa Biosciences successfully completed regulatory advice meeting with the Danish Medicines Agency
MonTa Biosciences have completed our regulatory meeting with the Danish Medicines Agency to align views [...]
MonTa Biosciences recruits Chief Medical Officer Steven Glazer to bring MonTas lead candidate MBS8 into clinical development
Steven Glazer is a well renowned clinical expert and biotech entrepreneur who has a strong [...]